About: Vaccine efficacy of a cell lysate with recombinant baculovirus-expressed feline infectious peritonitis (FIP) virus nucleocapsid protein against progression of FIP

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Vaccine efficacy of a cell lysate with recombinant baculovirus-expressed feline infectious peritonitis (FIP) virus nucleocapsid protein against progression of FIP Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Vaccine efficacy of a cell lysate with recombinant baculovirus-expressed feline infectious peritonitis (FIP) virus nucleocapsid protein against progression of FIP
Creator	Arai, Setsuo Hohdatsu, Tsutomu Kaneko, Miyuki Kaneshima, Takashi Koyama, Hiroyuki Kusuhara, Hajime Motokawa, Kenji Ohkawa, Tasuku Yamato, Hiroshi
Source	Elsevier; Medline; PMC
abstract	The Type II feline infectious peritonitis virus (FIPV) infection of feline macrophages is enhanced by a monoclonal antibody (MAb) to the S protein of FIPV. This antibody-dependent enhancement (ADE) activity increased with the MAb that showed a neutralizing activity with feline kidney cells, suggesting that there was a distinct correlation between ADE activity and the neutralizing activity. The close association between enhancing and neutralizing epitopes is an obstacle to developing a vaccine containing only neutralizing epitopes without enhancing epitopes. In this study, we immunized cats with cell lysate with recombinant baculovirus-expressed N protein of the Type I FIPV strain KU-2 with an adjuvant and investigated its preventive effect on the progression of FIP. Cats immunized with this vaccine produced antibodies against FIPV virion-derived N protein but did not produce virus-neutralizing antibodies. A delayed type hypersensitivity skin response to N protein was observed in these vaccinated cats, showing that cell mediated immunity against the FIPV antigen was induced. When these vaccinated cats were challenged with a high dose of heterologous FIPV, the survival rate was 75% (6/8), while the survival rate in the control group immunized with SF-9 cell-derived antigen was 12.5% (1/8). This study showed that immunization with the cell lysate with baculovirus-expressed N protein was effective in preventing the progression of FIP without inducing ADE of FIPV infection in cats.
has issue date	2003-12-02(xsd:dateTime)
bibo:doi	10.1016/j.vetmic.2003.09.016
bibo:pmid	14637036
has license	no-cc
sha1sum (hex)	0c97876a817259dcf4086eb29bb34d8db15ea9bb
schema:url	https://doi.org/10.1016/j.vetmic.2003.09.016
resource representing a document's title	Vaccine efficacy of a cell lysate with recombinant baculovirus-expressed feline infectious peritonitis (FIP) virus nucleocapsid protein against progression of FIP
has PubMed Central identifier	PMC7117512
has PubMed identifier	14637036
schema:publication	Vet Microbiol
resource representing a document's body	covid:0c97876a817259dcf4086eb29bb34d8db15ea9bb#body_text
is schema:about of	named entity 'NUCLEOCAPSID PROTEIN' named entity 'protein' named entity 'FIPV' named entity 'immunized' named entity 'progression' named entity 'CLOSE' named entity 'NEUTRALIZING ANTIBODIES' named entity 'HIGH DOSE' named entity 'VACCINATED' named entity 'PROGRESSION' named entity 'STUDY' named entity 'DISTINCT' named entity 'INVESTIGATED' named entity 'VIRUS' named entity 'MACROPHAGES' named entity 'ANTIGEN' named entity 'ENHANCED' named entity 'ASSOCIATION' named entity 'TYPE II' named entity 'BUT' named entity 'ACTIVITY' named entity 'SKIN RESPONSE' named entity 'OBSERVED' named entity 'CONTROL GROUP' named entity 'INDUCING' named entity 'CELLS' named entity 'WAS A' named entity 'BACULOVIRUS' named entity 'TYPE I' named entity 'CELL MEDIATED IMMUNITY' named entity 'DELAYED TYPE HYPERSENSITIVITY' named entity 'PRODUCE' named entity 'ANTIBODIES' named entity 'EXPRESSED' named entity 'FELINE INFECTIOUS PERITONITIS VIRUS' named entity 'ANTIBODY-DEPENDENT ENHANCEMENT' named entity '12.5' named entity 'SURVIVAL RATE' named entity 'RESPONSE TO' named entity 'S PROTEIN' named entity 'CORRELATION' named entity 'EFFECTIVE' named entity 'THESE' named entity 'ITS' named entity 'FELINE' named entity 'VIRION' named entity 'N PROTEIN' named entity 'FIP' named entity 'INCREASED' covid:arg/0c97876a817259dcf4086eb29bb34d8db15ea9bb named entity 'STRAIN' named entity 'IMMUNIZATION' named entity 'CONTAINING' named entity 'DERIVED' named entity 'EPITOPES' named entity 'PREVENTIVE EFFECT' named entity 'SF-9 CELL' named entity 'RECOMBINANT' named entity 'BACULOVIRUS' named entity 'CELL LYSATE' named entity 'EXPRESSED' named entity 'VACCINE EFFICACY' named entity 'FELINE INFECTIOUS PERITONITIS' named entity 'PROTEIN ' named entity 'DEVELOPING' named entity 'INDUCED' named entity 'ADE' named entity 'DID' named entity 'OBSTACLE' named entity 'KIDNEY' named entity 'ENHANCING' named entity 'MAB' named entity '2F8'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software